-
Posted by
Two Blokes Jul 14 -
Filed in
Stock
-
2 views
Capricor Therapeutics's dip caused by the Complete Response Letter is a buying opportunity considering the readout of HOPE-3 within 2-3 months. Based on HOPE-2 data and the expected course of Duchenne muscular dystrophy cardiomyopathy, I estimate a very high probability of a positive readout in HOPE-3, at least for cardiac endpoints. CAPR remains well funded through approval, not accounting for milestone payments, future royalty revenue, and a potential Priority Review Voucher worth $150M.
